Diabetes model derived from embryonic and pluripotent stem cells
Rudy Leibel, M.D.
Enables generation of therapeutic cells from directly from a patient.Provides a closely related model of the disease as the generated cells are derived directly from the patients themselves.Patients with rare disease mutations of diabetes may benefit from this technology because the efficacy of potential treatments may be tested first using this technology before being applied directly.Patent Information:Patent Pending
Method for generating beta cells for diagnostic and therapeutic applications.Efficient and reliable platform for studying cellular effects of diabetes mutations from the patient carrying the disease. In vitro testing platform for diabetes treatments.Protocols could be modified to derive other cell lines (i.e. hepatic, adipocyte, muscle, etc).
Rudy Leibel, M.D.
美國
